Use of lipid-based nutrient supplements by HIV-infected Malawian women during lactation has no effect on infant growth from 0 to 24 weeks

Abstract

The Breastfeeding, Antiretrovirals, and Nutrition Study evaluated the effect of daily consumption of lipid-based nutrient supplements (LNS) by 2121 lactating, HIV-infected mothers on the growth of their exclusively breast-fed, HIV-uninfected infants from 0 to 24 wk. The study had a 2 × 3 factorial design. Malawian mothers with CD4(+) ≥250 cells/mm(3), hemoglobin ≥70 g/L, and BMI ≥17 kg/m(2) were randomized within 36 h of delivery to receive either no LNS or 140 g/d of LNS to meet lactation energy and protein needs, and mother-infant pairs were assigned to maternal antiretroviral drugs (ARV), infant ARV, or no ARV. Sex-stratified, longitudinal, random effects models were used to estimate the effect of the 6 study arms on infant weight, length, and BMI. Logistic regression models were used to calculate the odds of growth faltering [decline in weight-for-age Z-score (WAZ) or length-for-age Z-score (LAZ) >0.67] using the control arm as the reference. Although some differences between study arms emerged with increasing infant age in boys, there were no consistent effects of the maternal supplement across the 3 growth outcomes in longitudinal models. At the ages where differences were observed, the effects on weight and BMI were quite small (≤200 g and ≤0.4 kg/m(2)) and unlikely to be of clinical importance. Overall, 21 and 34% of infants faltered in WAZ and LAZ, respectively. Maternal supplementation did not reduce the odds of infant weight or length faltering from 0 to 24 wk in any arm. These results indicate that blanket supplementation of HIV-infected lactating women may have little impact on infant growth.

Trial registration: ClinicalTrials.gov NCT00164736.

Conflict of interest statement

Author disclosures: C. M. van der Horst received grant support from Abbott Laboratories and GlaxoSmithKline. V. L. Flax, M. E. Bentley, C. S. Chasela, D. Kayira, M. G. Hudgens, R. J. Knight, A. Soko, D. J. Jamieson, and L. S. Adair, no conflicts of interest.

Figures

FIGURE 1

Boys’ predicted weight through age 6 mo in the mLNS, mLNS-mARV, and mLNS-iARV arms of the longitudinal model (A) and in the C, mARV, and iARV arms of the longitudinal model (B). C, control; iARV, infant antiretroviral drug; mARV, maternal antiretroviral drug; mLNS, maternal lipid-based nutrient supplement; mLNS-iARV, maternal lipid-based nutrient supplement/infant antiretroviral drug; mLNS-mARV, maternal lipid-based nutrient supplement/maternal antiretroviral drug.